Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.

Takeda Pharmaceuticals: Global Homepage

# FY2023 Q2 Financial Results



We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.

Title

**OSAKA, Japan, and CAMBRIDGE, Massachusetts, October 26, 2023** – Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/stock-information/)) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Management Guidance for Core growth at Constant Exchange Rate. For details, please see [here](https://assets-dam.takeda.com/image/upload/v1698287672/Global/Investor/Financial-Results/FY2023/Q2/Q2_FY2023_Press_Release_FINAL.pdf). 


Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2024. For the details, please see [here](https://assets-dam.takeda.com/image/upload/v1698283723/Global/Investor/Financial-Results/FY2023/Q2/E_Press_Release_FY2023_Q2_Revised_Forecast.pdf).


Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)

ADCETRIS receives EC approval for extension of marketing authorization in combination therapy for previously untreated Hodgkin lymphoma patients

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

<h2 style="text-align: center;">Recent News</h2>



Work with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.


### Join Us



/careers

Discover our balanced, diverse portfolio and strategy for sustainable, patient-centered and resilient growth.


### Investors



/investors/overview

Fueled by our inherent curiosity, we translate science into highly innovative, life-transforming medicines.


### R\&D



/science/research-and-development

## Better Health, Brighter Future



Understanding and addressing life-limiting gastrointestinal and inflammatory diseases

Working to transform treatments in immunology, hematology, metabolic and lysosomal storage disorders

Improving the lives of patients with rare and complex chronic diseases through innovation in plasma

Aspiring to cure cancer, with inspiration from patients and innovation from everywhere

Driving medical innovation for patients with neurological diseases

Addressing unmet global health needs through vaccine development against infectious diseases

## Our Areas of Focus


Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

## Sign up for investors newsletter



Cancel

Links to sites outside of takeda.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


FY2023 Q2 Financial Results

Recent News

Title

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Better Health, Brighter Future

Join Us

Investors

R&D

Our Areas of Focus

Gastrointestinal and Inflammation

Rare Diseases

Plasma-Derived Therapies

Oncology

Neuroscience

Vaccines